{"id":527,"date":"2007-11-01T12:00:00","date_gmt":"2007-11-01T11:00:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2007\/ibandronat-und-zoledronat-intravenoes-applizierbare-bisphosphonate-bei-postmenopausaler-osteoporose"},"modified":"2007-11-01T12:00:00","modified_gmt":"2007-11-01T11:00:00","slug":"ibandronat-und-zoledronat-intravenoes-applizierbare-bisphosphonate-bei-postmenopausaler-osteoporose","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2007\/ibandronat-und-zoledronat-intravenoes-applizierbare-bisphosphonate-bei-postmenopausaler-osteoporose","title":{"rendered":"Ibandronat und Zoledronat: Intraven\u00f6s applizierbare Bisphosphonate bei postmenopausaler Osteoporose"},"content":{"rendered":"<p>Zusammenfassung: Die intraven\u00f6se Gabe von Bisphosphonaten (BP) bei Osteoporose ist bei Kontraindikationen f\u00fcr die orale Zufuhr indiziert oder bei Patient(inn)en, die die umst\u00e4ndliche orale Einnahmeprozedur zu umgehen w\u00fcnschen und\/oder l\u00e4ngere Behandlungsintervalle vorziehen. Mit Ibandronat (Bonviva\u00ae 3 mg\/ml Fertigspritze, zugelassen seit M\u00e4rz 2006) und Zoledronat (Aclasta\u00ae, zugelassen seit Oktober 2007) stehen zwei stickstoffhaltige BP f\u00fcr die [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zusammenfassung: Die intraven\u00f6se Gabe von Bisphosphonaten (BP) bei Osteoporose ist bei Kontraindikationen f\u00fcr die orale Zufuhr indiziert oder bei Patient(inn)en, die die umst\u00e4ndliche orale Einnahmeprozedur zu umgehen w\u00fcnschen und\/oder l\u00e4ngere Behandlungsintervalle vorziehen. Mit Ibandronat (Bonviva\u00ae 3 mg\/ml Fertigspritze, zugelassen seit M\u00e4rz 2006) und Zoledronat (Aclasta\u00ae, zugelassen seit Oktober 2007) stehen zwei stickstoffhaltige BP f\u00fcr die [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[386,145,1101,1103,1102,1105,1104,1106,70,1100,1099,1096,1098,1097],"class_list":["post-527","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-alendronat","tag-bisphosphonate","tag-bone-studie","tag-diva-studie","tag-fit-studie","tag-hip-studie","tag-horizon-studie","tag-ibandronat","tag-osteoporose","tag-risedronat","tag-risedronsaeure","tag-vert-studie","tag-zoledronat","tag-zoledronsaeure"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/527","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=527"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/527\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=527"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=527"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=527"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}